Financials
Financial year 2025
KEMPEN PHARMA from Wuustwezel, company number BE0538871226, closed financial year 2025 with a result of € 647,955 after tax. For that financial year KEMPEN PHARMA recorded a gross margin of € 259,794 and equity of € 2.7 million. Compared with financial year 2024, the result moved from € 224,238 to € 647,955. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 17, 2026.
€ 2.7 million
▲ 23% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 647,955
▲ 189% vs 2024
Profit after tax over the fiscal year.
€ 18,970
▼ 70% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 145,800 paid out
23 % of the profit went to the shareholders, the rest stayed in the company.
Debts at end 2025
€ 665,456
▼ 21% vs 2024
€ 188,718 is repaid this year. At this pace the long-term loan is gone in ≈ 4 years.
€ 66
Supplier invoices still open on the last day of the fiscal year.
€ 102,842
▼ 3% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 250,802 | € 260,179 | € 261,112 | € 259,794 | ▼ 1% |
| Profit after taxes | € 179,868 | € 700,790 | € 224,238 | € 647,955 | ▲ 189% |
| Equity | € 1,317,010 | € 1,987,800 | € 2,184,318 | € 2,686,473 | ▲ 23% |
| Total debts | € 1,866,457 | € 1,233,113 | € 1,058,352 | € 882,024 | ▼ 17% |
| Cash | € 63,455 | € 41,177 | € 63,396 | € 18,970 | ▼ 70% |
| Retained profit | € 1,298,460 | € 1,969,250 | € 2,165,768 | € 2,667,923 | ▲ 23% |
| Dividend | € 30,000 | € 30,000 | € 27,720 | € 145,800 | ▲ € 118,080 |
| Bank debt | € 1,343,362 | € 1,021,246 | € 847,667 | € 665,456 | ▼ 21% |
| Balance sheet total | € 3,183,467 | € 3,220,913 | € 3,242,670 | € 3,568,497 | ▲ 10% |
Key figures of KEMPEN PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to KEMPEN PHARMA?
What happened at KEMPEN PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 647,955 (▲ 189% vs 2024). filed late Source: NBB ↗
- Ineke Kempen became a director. NBB
- Start of the company according to the CBE. KBO
In short
From € 179,868 profit in 2022 to € 647,955 profit in 2025.
Paid € 373,979 in corporate taxes since 2022.
Best year ever: 2023, with € 700,790 profit.
Paid out € 233,520 in dividends to the owners in total.
Management
Behind KEMPEN PHARMA is Ineke Kempen. It owns 100% of NV Medigrex and 35.4% of BV Gooreind Pharma itself.
Directors
According to the 2025 annual accounts
Ineke Kempen
Director
since 2013
Establishments
Establishment units
Physical locations of this company
Wiezelo 11
2990 Wuustwezel
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0538.871.226
- VAT number
- BE 0538.871.226
- Registered office
- Wiezelo 11, 2990 Wuustwezel
- Names & denominations
- KEMPEN PHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 18 September 2013
- Peppol
- Active · Active since 27 Nov 2025
- Activities · NACE
Activiteiten van holdings
Holdings